StockData

Q32 Bio vs Roivant Sciences

QTTB and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QTTB and ROIV compare

Roivant Sciences is the larger company, worth 109 times as much as Q32 Bio ($28.0B against $257M).

Q32 Bio scores higher on the StockData Score (8 against 7 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQTTBROIV
Size and price
Market cap$257M$28.0B
Share price$8.63$38.71
Change, 1 year300%90.8%
Change, 5 years−90.8%453%
Beta (5Y)−0.980.42
Employees24721
StockData Score
Total score8 (better)7
Valuation score00
Growth score1 (better)0
Performance score11
Health score66
Dividend score00
Valuation
P/S–3712×
P/B2.4× (better)6.6×
EV/EBITDA7.0×–
FCF yield–−2.9%
Growth
Revenue growth (TTM)–−67.6%
Revenue growth, 5Y average81.9% (better)−19.1%
Profitability
Operating margin–−7915%
Net margin–−3535%
FCF margin–−10901%
Return on equity72.1% (better)−6.2%
Return on invested capital–−407%
Financial health
Debt / equity0.000.00
Current ratio20.30 (better)16.72
Altman Z-score14.4944.02 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−4.0%–
Shareholder yield−4.0%0.00% (better)
Ownership
Held by institutions74.6%78.1%
Held by insiders28.9%13.9%
Insider net buying, 12 months$29.5M (better)−$798M
Superinvestors holding–1
Short interest, % of float26.4%7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.